Literature DB >> 27462391

Early surgery in Crohn's disease a benefit in selected cases.

Vinna An1, Lauren Cohen1, Matthew Lawrence1, Michelle Thomas1, Jane Andrews1, James Moore1.   

Abstract

AIM: To compare the outcomes of a cohort of Crohn's disease (CD) patients undergoing early surgery (ES) to those undergoing initial medical therapy (IMT).
METHODS: We performed a review of a prospective database CD patients managed at a single tertiary institution. Inclusion criteria were all patients with ileal or ileocolonic CD between 1995-2014. Patients with incomplete data, isolated colonic or perianal CD were excluded. Primary endpoints included the need for, and time to subsequent surgery. Secondary endpoints included the number and duration of hospital admissions, and medical therapy.
RESULTS: Forty-two patients underwent ES and 115 underwent IMT. The operative intervention rate at 5 years in the ES group was 14.2% vs IMT 31.3% (HR = 0.41, 95%CI: 0.23-0.72, P = 0.041). The ES group had fewer hospital admissions per patient [median 1 vs 3 (P = 0.012)] and fewer patients required anti-TNF therapy than IMT (33.3% vs 57%, P = 0.003). A subgroup analysis of 62 IMT patients who had undergone surgery were compared to ES patients, and showed similar 5 year (from index surgery) re-operation rates 16.1% vs 14.3%. In this subset, a significant difference was still found in median number of hospital admissions favouring ES, 1 vs 2 (P = 0.002).
CONCLUSION: Our data supports other recent studies suggesting that patients with ileocolonic CD may have a more benign disease course if undergoing early surgical intervention, with fewer admissions to hospital and a trend to reduced overall operation rates.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Operation; Surgery; Terminal ileitis

Year:  2016        PMID: 27462391      PMCID: PMC4942749          DOI: 10.4240/wjgs.v8.i7.492

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  31 in total

1.  The effects of infliximab maintenance therapy on health-related quality of life.

Authors:  Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

3.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

Review 4.  Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor α agents - a systematic review.

Authors:  Alaa El-Hussuna; Klaus Theede; Gunnar Olaison
Journal:  Dan Med J       Date:  2014-12       Impact factor: 1.240

5.  Rates of early surgery and associated risk factors in Crohn's disease.

Authors:  Su Jin Jeon; Kwang Jae Lee; Myung Hee Lee; Seon Kyo Lim; Chang Jun Kang; Jin Hong Kim
Journal:  Korean J Gastroenterol       Date:  2010-10

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.

Authors:  E V Loftus; P Schoenfeld; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

8.  Is early limited surgery associated with a more benign disease course in Crohn's disease?

Authors:  Petra Anna Golovics; Laszlo Lakatos; Attila Nagy; Tunde Pandur; Istvan Szita; Mihaly Balogh; Csaba Molnar; Erzsebet Komaromi; Barbara Dorottya Lovasz; Michael Mandel; Gabor Veres; Lajos S Kiss; Zsuzsanna Vegh; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn's disease.

Authors:  Xiang Gao; Rong-Ping Yang; Min-Hu Chen; Ying-Lian Xiao; Yao He; Bai-Li Chen; Pin-Jin Hu
Journal:  Scand J Gastroenterol       Date:  2012-07-31       Impact factor: 2.423

10.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

View more
  8 in total

1.  Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease.

Authors:  Éanna J Ryan; Gabriel Orsi; Michael R Boland; Adeel Zafar Syed; Ben Creavin; Michael E Kelly; Kieran Sheahan; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; Des C Winter; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-01-09       Impact factor: 2.571

2.  Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.

Authors:  Michał Łodyga; Piotr Eder; Magdalena Gawron-Kiszka; Agnieszka Dobrowolska; Maciej Gonciarz; Marek Hartleb; Maria Kłopocka; Ewa Małecka-Wojciesko; Piotr Radwan; Jarosław Reguła; Edyta Zagórowicz; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2021-11-19

Review 3.  Aspects Towards the Anastomotic Healing in Crohn's Disease: Clinical Approach and Current Gaps in Research.

Authors:  F H M Chaim; L M V Negreiros; K M Steigleder; N S N Siqueira; L M Genaro; P S P Oliveira; C A R Martinez; M L S Ayrizono; J J Fagundes; R F Leal
Journal:  Front Surg       Date:  2022-06-24

4.  Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn's disease: a systematic review and meta-analysis.

Authors:  Waqas T Butt; Éanna J Ryan; Michael R Boland; Eilis M McCarthy; Joseph Omorogbe; Karl Hazel; Gary A Bass; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-02-11       Impact factor: 2.571

5.  Inclusion of the Mesentery in Ileocolic Resection for Crohn's Disease is Associated With Reduced Surgical Recurrence.

Authors:  Calvin J Coffey; Miranda G Kiernan; Shaheel M Sahebally; Awad Jarrar; John P Burke; Patrick A Kiely; Bo Shen; David Waldron; Colin Peirce; Manus Moloney; Maeve Skelly; Paul Tibbitts; Hena Hidayat; Peter N Faul; Vourneen Healy; Peter D O'Leary; Leon G Walsh; Peter Dockery; Ronan P O'Connell; Sean T Martin; Fergus Shanahan; Claudio Fiocchi; Colum P Dunne
Journal:  J Crohns Colitis       Date:  2018-11-09       Impact factor: 9.071

Review 6.  Surgical Management of Small Bowel Crohn's Disease.

Authors:  Pramodh Chandrasinghe
Journal:  Front Surg       Date:  2022-04-15

7.  Management and outcomes of patients with Crohn's disease with first vs multiple surgeries: results from the PRACTICROHN study.

Authors:  Marisa Iborra; Berta Juliá; Maria Dolores Martín Arranz; Manuel Barreiro-de Acosta; Ana Gutiérrez; Valle García-Sánchez; Carlos Taxonera; Javier P Gisbert; Luis Cea-Calvo; Eugeni Domènech
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-07-19

8.  Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial.

Authors:  Xiuxiu Hao; Tienan Feng; Yang Yang; Yuan Shi; Ran Jing; Sailiang Liu; Yang Luo; Yuqi Qiao; Ming Zhong; Minhao Yu
Journal:  BMJ Open       Date:  2020-11-16       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.